Idorsia Ltd Idorsia Ltd

Idorsia Ltd

IDIA

Rank in Stocks #7690
Idorsia Ltd, a biopharmaceutical company, engages in the discovery,... Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The companyโ€™s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Share Price
$4.74
Last synced: 2026-11-12
Market Cap
$1.26B
Change (1 day)
-2.37%
Change (1 year)
19.13%
Country

Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this

Category

Healthcare
Operating Margin for Idorsia Ltd (IDIA)
Operating Margin as of November 2026 TTM: -106.46%
According to Idorsia Ltd's latest financial reports, its current operating margin (TTM) is -106.46%. At the end of 2025 the company had an operating margin of -59.28%.
Operating Margin history for Idorsia Ltd from 2016 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -106.46% 79.59%
2025 -59.28% -71.25%
2024 -206.22% 23.17%
2023 -167.43% -79.75%
2022 -826.93% -52.31%
2021 -1,734.15% 203.08%
2020 -572.18% -71.75%
2019 -2,025.36% 230.86%
2018 -612.15% 12,167.54%
2017 -4.99% 0.00%
2016 0.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -98.16%
US
33.87% -100.32%
US
-116.04% -98.91%
US
25.57% -100.24%
AU
31.23% -100.29%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Idorsia Ltd's operating margin

What is Idorsia Ltd's operating margin?

Idorsia Ltd's operating margin is -106.46%, as of Nov 2026.

What was Idorsia Ltd's operating margin in 2025?

In 2025, Idorsia Ltd's operating margin was -59.28%, compared with -206.22% in 2024.

How has Idorsia Ltd's operating margin changed since 2020?

From 2020 to 2025, Idorsia Ltd's operating margin was highest in 2025 (-59.28%) and lowest in 2021 (-1,734.15%).

How does Idorsia Ltd's operating margin compare with similar companies?

Idorsia Ltd's operating margin (-106.46%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.